Sanofi SA (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 244   

Articles published

SNY 55.88 -0.55 (-0.97%)
price chart
Sanofi, Regeneron Release Data For Sinusitis Drug
Sanofi SA (ADR) (SNY) and Regeneron Pharmaceuticals Inc. (REGN) have released positive data from a Phase IIa study for their investigational drug dupilumab.
Related articles »  
Sanofi Still Ahead Of Novo Nordisk In Insulin Drug Race
Novo Nordisk A/S (ADR) (NVO) announced yesterday, that its insulin therapy Tresiba, which was in late-stage trials, has proved to be safe and effective for the treatment of type 1 diabetes in children and young adults.
Related articles »  
Sanofi Partners With US-Based Startup For Genetic Heart Disease Drugs
Sanofi SA (ADR) (SNY) announced early Wednesday, its decision to partner with US-based, privately held MyoKardia for the development of first-of-their-kind medicinal therapies designed for individuals suffering from genetic heart diseases.
Related articles »  
Eli Lilly Gets EC Approval For Biosimilar Version Of Sanofi's Lantus
The new drug is a biosimilar version of Sanofi SA (ADR)'s (SNY) blockbuster insulin glargine Lantus and the first biosimilar insulin to be approved in Europe.
Related articles »  
Sanofi Releases Positive Data For New MS Drug
Sanofi's subsidiary, Genzyme, is working on a Multiple Sclerosis (MS) drug called Lemtrada. Data revealed by the company indicates that the drug has remained effective in patients even after four years of treatment, and has reduced relapse rates as well.
Related articles »  
Sanofi Reports Positive Results For Dengue Vaccine
France based Sanofi SA (ADR) (SNY) announced today that the world's first vaccine against dengue fever, which was in its late stage clinical trials, was able to reduce disease cases by 60.8%.
Related articles »  
Sanofi And Regeneron Announce Positive Results For Cholesterol Drug ...
Sanofi SA (ADR) (SNY) and Regeneron Pharmaceuticals Inc. (REGN) announced over the weekend that their experimental drug Alirocumab significantly cut the level of cholesterol in four trials, indicating that the treatment may prevent heart disease and ...
Related articles »  
Sanofi's Menactra Gets FDA Approval As Booster Vaccine
Sanofi SA (ADR) (SNY) announced yesterday, that it has won the approval of the US Food and Drug Administration (FDA) for a label expansion of its meningococcal vaccine Menactra for use as a booster shot.
Related articles »  
Health stocks in focus: Novartis AG (NYSE:NVS), Sanofi SA (ADR) (NYSE:SNY ...
On September 23, Sanofi SA (ADR) (NYSE:SNY) said that it had plans to add Oral GLP-1, a diabetes drug, to its product offerings.
Trending Stocks: ALIBABA GROUP HOLDING (NYSE:BABA), Sanofi SA (ADR ...
On September 19, Sanofi SA (ADR) (NYSE:SNY) announced early Wednesday, its decision to partner with US-based, privately held MyoKardia for the development of first-of-their-kind medicinal therapies designed for individuals suffering from genetic heart ...
Related articles »